Stockreport

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential [Yahoo! Finance]

MAIA Biotechnology, Inc.  (MAIA) 
PDF telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: MAIA) advances through mid- to late-stage clinical development. Newly filed disclosures sho [Read more]